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Coronary heart disease (CHD) is the leading cause of mortality in African Americans. To identify common genetic
polymorphisms associated with CHD and its risk factors (LDL- and HDL-cholesterol (LDL-C and HDL-C), hypertension,
smoking, and type-2 diabetes) in individuals of African ancestry, we performed a genome-wide association study (GWAS) in
8,090 African Americans from five population-based cohorts. We replicated 17 loci previously associated with CHD or its risk
factors in Caucasians. For five of these regions (CHD: CDKN2A/CDKN2B; HDL-C: FADS1-3, PLTP, LPL, and ABCA1), we could
leverage the distinct linkage disequilibrium (LD) patterns in African Americans to identify DNA polymorphisms more
strongly associated with the phenotypes than the previously reported index SNPs found in Caucasian populations. We also
developed a new approach for association testing in admixed populations that uses allelic and local ancestry variation.
Using this method, we discovered several loci that would have been missed using the basic allelic and global ancestry
information only. Our conclusions suggest that no major loci uniquely explain the high prevalence of CHD in African
Americans. Our project has developed resources and methods that address both admixture- and SNP-association to
maximize power for genetic discovery in even larger African-American consortia.
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Introduction
Coronary heart disease (CHD) is the leading cause of mortality
in African-American men and women [1]. The risk factors for
CHD in African Americans are similar to those reported in
Caucasians, but their relative impact varies between the two ethnic
groups. Multiple studies have reported that smoking, type-2
diabetes (T2D), hypertension, and LDL- and HDL-cholesterol
(LDL-C and HDL-C) are significant independent risk factors for
CHD in African Americans [2–5]. In general, hypertension and
LDL-C have a larger and smaller impact on CHD risk,
respectively, in African Americans compared with Caucasians
[3]. There is also extensive evidence of the role of genetic factors in
the familial aggregation of CHD and its predictors in African
Americans [6]. However, the underlying genes remain largely
unknown.
Recent advances in genome-wide association studies (GWAS)
have made spectacular advances in identifying genes contributing
to numerous common chronic diseases in Europeans and
European Americans [7]. There are multiple loci convincingly
associated with CHD risk in Caucasians, including many genes
involved in lipid metabolism, as well as novel chromosomal
regions that do not appear to contribute to risk through traditional
risk factors [7–14]. However, there have been no large-scale
GWAS for CHD and its risk factors in African Americans. GWAS
in African Americans is important because new genes may be
identified as a result of genetic variation private to populations of
African-descent, differences in allele frequencies and in patterns of
linkage disequilibrium (LD), differences in the relative impact of
risk factors to disease, or differences in gene-environment
interactions. Here we report a large (and for most phenotypes
first) GWAS for CHD, type-2 diabetes (T2D), hypertension, LDL-
C and HDL-C, and smoking in 8,090 African Americans as part of
the National Heart, Lung, and Blood Institute (NHLBI)-sponsored
Candidate gene Association Resource (CARe) Project [15].
Results
We genotyped 909,622 single nucleotide polymorphisms in
9,119 African Americans from the ARIC (N=3,269), CARDIA
(N=1,209), CFS (N=704), JHS (N=2,200), and MESA
(N=1,737) population-based cohorts, on the Affymetrix Ge-
nome-Wide Human SNP Array 6.0 platform. Genotypes were
called using Birdseed v1.33 [16], and stringent quality-control
filters were applied (Tables S1 and S2). For samples that passed
quality control (N=8,100), principal component analysis (PCA)
using EIGENSTRAT [17] revealed only ten population outliers
across all cohorts; these samples were also excluded from the
analysis (Text S1 and Figure S1). Overall, a total of 8,090 African
Americans with very high genotype quality (average genotype
success rate of 99.65%) were available for analysis. The
demographics of these participants by cohort are shown in
Table 1. To increase our coverage of common genetic variation
and statistical power, and to facilitate comparisons across
GWAS of CHD in African Americans
PLoS Genetics | www.plosgenetics.org 2 February 2011 | Volume 7 | Issue 2 | e1001300genotyping platforms, we imputed genotypes in the CARe
African-American populations using MACH taking into account
the admixed nature of the population (Text S1) [18,19].
For all cohorts except CFS, single marker genetic association
tests were performed by study using PLINK v1.06 [20] under an
additive genetic model. We used linear regression for quantitative
traits (HDL-C, LDL-C, and smoking) and logistic regression for
dichotomous phenotypes (CHD, hypertension, and T2D). For
CFS, family structure was modeled using linear mixed effects
(LME) models and generalized estimating equations (GEE) for
quantitative and dichotomous phenotypes, respectively [21]. For
all analyses, the first ten principal components were used as
covariates to account for global admixture and population
stratification. A detailed description of the analysis methods and
the phenotypic definitions used can be found in Text S1. Power
calculations for the different phenotypes analyzed are summarized
in Table S3; we have excellent power to find strong signals, but
low to modest power for variants with weak phenotypic effects.
The inflation factors (ls) observed were all near unity (Table S4),
suggesting that most confounders, including population stratifica-
tion, were well-controlled.
We applied genomic control to the individual cohorts’ results
and combined them using the inverse variance meta-analysis
method [22]. Inflation factors of the meta-analysis results were
modest and were again scaled using genomic control (Table S4).
Quantile-quantile (QQ) plots of the six different meta-analyses
after double genomic control corrections show that the test
statistics follow the null expectations, except for the HDL-C and
LDL-C meta-analyses, which show an upward departure from the
null distributions at the lowest P-values (Figure 1). This departure
is caused by known genetic variants with large effects on lipid
levels (Figure S2).
The main goal of this study was to identify new genetic risk
factors for CHD and its predictors in African Americans. For five
Author Summary
To date, most large-scale genome-wide association studies
(GWAS) carried out to identify risk factors for complex
human diseases and traits have focused on population of
European ancestry. It is currently unknown whether the
same loci associated with complex diseases and traits in
Caucasians will replicate in population of African ancestry.
Here, we conducted a large GWAS to identify common
DNA polymorphisms associated with coronary heart
disease (CHD) and its risk factors (type-2 diabetes,
hypertension, smoking status, and LDL- and HDL-choles-
terol) in 8,090 African Americans as part of the NHLBI
Candidate gene Association Resource (CARe) Project. We
replicated 17 associations previously reported in Cauca-
sians, suggesting that the same loci carry common DNA
sequence variants associated with CHD and its risk factors
in Caucasians and African Americans. At five of these 17
loci, we used the different patterns of linkage disequilib-
rium between populations of European and African
ancestry to identify DNA sequence variants more strongly
associated with phenotypes than the index SNPs found in
Caucasians, suggesting smaller genomic intervals to search
for causal alleles. We also used the CARe data to develop
new statistical methods to perform association studies in
admixed populations. The CARe Project data represent an
extraordinary resource to expand our understanding of the
genetics of complex diseases and traits in non-European-
derived populations.
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cohorts for smoking), we identified SNPs with the strongest
evidence of association in the CARe meta-analysis – SNPs were
selected after accounting for LD to limit association signals
redundancy – and sought replication using in silico data or direct
genotyping in independent African-American cohorts (Table 1).
Combined results from a meta-analysis of the CARe and
replication data are presented in Tables S5, S6, S7, S8, S9 and
summarized in Table 2. We identified one novel locus that reached
the generally accepted level for genome-wide significance
(P#5610
28):SNP rs7801190 inthe potassium/chloridetransporter
gene SLC12A9 and hypertension (OR=1.31, combined
P=3.4610
28). Despite reaching genome-wide significance, we
are cautious in highlighting this association because it was identified
using imputed genotypes (imputation quality r
2_hat=0.70) and the
replication result, also obtained by imputation, was not statistically
significant (P=0.29). Indeed, when we directly assessed the quality
of the imputation by directly genotyping rs7801190 in ARIC
African-American samples (N=2,572), we failed to validate the
observed association with hypertension. This result suggests that the
association between rs7801190 and hypertension status observed in
the CARe African-American datasets is likely due to chance.
To validate our phenotype modeling and analytical strategy, we
sought to replicate in the CARe meta-analyses genetic associations
previously reported in populations of European ancestry. We
retrieved all index SNPs associated at genome-wide significance
Figure 1. Quantile-quantile (QQ) plots of the meta-analyses for coronary heart disease, HDL-C, hypertension, LDL-C, smoking, and
type-2 diabetes analyzed in the CARe African-American samples (N=8,090). Each black circle represents an observed statistic for all
genotypes and imputed SNPs (defined as the 2log10(P-value)) against the corresponding expected statistic. The grey area corresponds to the 90%
confidence intervals calculated empirically using permutations. The meta-analysis inflation factors are: coronary heart disease (ls=0.991), HDL-C
(ls=1.030), hypertension (ls=1.024), LDL-C (ls=1.023), smoking (ls=1.008), and type-2 diabetes (ls=1.017). Data shown are genomic controlled
before (for each study) and after the meta-analysis.
doi:10.1371/journal.pgen.1001300.g001
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smoking in Caucasians as well as their proxy SNPs (defined as
markers with an r
2$0.5 with the index SNPs in HapMap samples
of European ancestry (CEU)) (Table S10) [23]. We then
determined whether there was also evidence of association for
the same signals in this large sample of African Americans. We
detected modest to strong evidence of replication for one locus
associated with CHD, one locus with T2D, nine with HDL-C, and
six with LDL-C (Table 3 and Table S11). We did not replicate
signals associated with smoking or hypertension. Furthermore, the
top ten associated SNPs in a recent hypertension GWAS
performed in African Americans [24] were not associated with
hypertension in the CARe meta-analysis (different direction of
effect and/or P.0.05). Since these hypertension association
signals did not replicate in the original publication, non-replication
here may result from their being falsely positive in the original
report. Although replication of some of the above loci in African-
derived populations had been reported previously [25], for most of
them, the CARe results represent the first replication in
populations of African ancestry.
Taking advantage of the LD patterns in African Americans (LD
breakdown over shorter distances compared with Caucasians), we
assessed whether we could fine-map some of the associations
previously reported in Caucasians. For this, we evaluated SNPs
that were correlated with the index SNP in HapMap CEU
(r
2$0.5), but largely uncorrelated with it in HapMap samples of
African descent (YRI)(r
2#0.1). In most cases, the same signals
were responsible for the associations in Caucasians and African
Americans (Table 3 and Table S11). However, we found five
examples where the predominant association signals were at SNPs
strongly correlated with the index SNPs in HapMap CEU but
weakly or not correlated with the index SNPs in HapMap YRI:
the CDKN2A/CDKN2B locus for CHD and the FADS1-3, PLTP,
LPL, and ABCA1 loci for HDL-C (Table S12). Using available
genetic association results for myocardial infarction [10] and
HDL-C [26] in Caucasians, we illustrate in Figure 2 and Figure S3
how our results in African Americans can help refine association
signals. For instance, for the FADS locus, the index SNP in
Caucasians (rs174547) is in strong LD with the top SNP in the
CARe African-American meta-analysis (rs1535) in HapMap CEU
(r
2=1) but not in HapMap YRI (r
2=0.09). The region of strong
LD around rs174547 in HapMap CEU is 113 kb wide and
includes the three FADS genes, whereas rs1535, located in an
intron of FADS2, is in strong LD with no other markers in
HapMap YRI (Figure 2). Comparison of association signals
regionally in African Americans and European-derived individuals
can thus be useful in two ways: (1) they may suggest smaller
chromosomal regions for re-sequencing experiments to attempt to
identify causal variant(s) that underlie shared signals between
African- and European-derived chromosomes or (2) they may
indicate that the index SNPs for African and European
populations are linked to distinct causal variants. A third
potentially interesting result from trans-ethnic comparison of
association results is the identification of ethnic-specific association
signals. For instance, at the ABCA1 locus, three SNPs in LD
(rs4743763, rs4149310, and rs2515629) are associated with
HDL-C in CARe African Americans (P,1610
25), but not in
Caucasians (Figure S3D).
The optimal analytical strategy for GWAS in recently admixed
populations has not been established. In African Americans, an ideal
test statistic would incorporate both genotype information as
traditionally used in GWAS, but also, at each locus, the probability
that a given individual has zero, one, or two copies of a European (or
African) chromosomal segment. This method would be particularly
informativeinacasewhere,forexample,thecausalalleleisnotinLD
with any markers on the genotyping array, but is at higher frequency
on one ancestral background. To explore the benefits of such a
statistical framework, we designed and applied a novel method that
combines evidence of association from genotypes and local ancestry
estimates; the method is described in details in Text S1. Briefly, we
use a panel of ancestry informative markers across the genome and a
new implementation of the software ANCESTRYMAP [27] to
estimate, for each of the CARe African Americans genotyped, the
probabilistic proportion of European ancestry (0–100%) at the locus
for each of the ,900,000 SNPs genotyped on the Affy6.0 platform.
For each SNP, we can then compute association between the
phenotype and both the SNP genotype and the SNP estimate of local
ancestry to generate a combined score that summarizes allelic
variation and admixture. This method was used to produce the
association data presented in Table 4.
Our method to assess combined SNP- and ancestry-association was
tested explicitly on CHD and its risk factors in the CARe African-
Table 2. Novel genetic associations (P#1610
26) between SNPs and coronary heart disease or its risk factors in African Americans.
Trait SNP
CHR
(POS)1
Reference
allele
(reference
allele
frequency)2 CARe meta-analysis Replication Combined Locus
OR [95% CI]
or Beta (SE)
3 P-value
4
OR [95% CI]
or Beta (SE)
3 P-value
OR [95% CI]
or Beta (SE)
3 P-value
HDL-C rs7323893 13
(87502707)
T (0.91) 20.138
(0.030)
5.7610
26 20.131
(0.047)
0.0053 20.136
(0.025)
1.3610
27
rs937254 15
(55697456)
A (0.57) 0.077
(0.017)
5.4610
26 0.078
(0.043)
0.067 0.077
(0.016)
1.0610
26 GCOM1
Hypertension rs7801190 7
(100296029)
C (0.73) 1.35
[1.22–1.50]
2.5610
28 1.13
[0.90–1.44]
0.29 1.31
[1.19–1.44]
3.4610
28 SLC12A9
LDL-C rs13161895 5
(179403807)
T (0.08) 0.151
(0.035)
2.3610
25 0.139
(0.052)
0.0077 0.147
(0.029)
5.8610
27 RNF130
1Coordinates are on NCBI build 36.1.
2Average frequency for the reference allele across all available African-American CARe samples.
3Direction of the effect given for the reference allele; OR, odds ratio; CI, confidence interval; SE, standard error.
4P-values are scaled using genomic control.
doi:10.1371/journal.pgen.1001300.t002
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test statistic obtained using the SNP-alone or the SNP+admixture
information (in both methods, global ancestry is included as a
covariate), focusing on markers thatw o u l dn o th a v eb e e np r i o r i t i z e d
for follow-up replication when considering only SNP genotype
association results (Figure S6). Across the six phenotypes, we identified
12 SNPs outside the previously known loci with a P#1610
26 in this
SNP+admixture test statistic (Table 4). Most of these SNPs have a large
allele frequency difference between the HapMap CEU and YRI
individuals, suggesting that local ancestry might confound simple SNP
association testing. For instance, the frequency of the C-allele at
rs8078633 near the APPBP2 gene is 100% and 18% in CEU and YRI,
respectively. The association between this SNP and HDL-C levels is
weak when considering only allelic variation (P=0.98) but becomes
highly significant when evidence from the genotype and the estimate of
local ancestry is combined (P=3.6 610
27) (Table 4). This composite
approach also identified a SNP near the phospholipase B1 gene (PLB1)
that is strongly associated with LDL-C levels (P=4.1 610
28), but that
would not have been noticed using traditional genotype-only
association testing (P=0.23) (Table 4). As more large-scale GWAS in
individuals of African ancestry are completed, it will be important to
replicate these results.
Table 3. Replication of associations previously reported in Caucasians in the CARe African-American meta-analyses.
Trait Locus Chr. CARe SNP
a Position
b
Effect
allele
c
Average
effect allele
frequency in
CARe (SE)
Odds ratio/
Beta
d 95% CI/SE
d P-value
e Reference
Coronary
heart disease
CDKN2A,
CDKN2B
9 rs4977574 22088574 G 0.177 (0.004) 1.18 (OR) [0.93–1.49] 0.17 [10]
9 rs6475606 (p) 22071850 C 0.109 (0.003) 2.00 (OR) [1.34–2.96] 6.4610
24
Type-2
diabetes
TCF7L2 10 rs7903146 114748339 T 0.291 (0.005) 1.33 (OR) [1.19–1.48] 3.5610
27 [29]
HDL-C GALNT2 1 rs2144300 228361539 T 0.143 (0.012) 0.092 (BETA) 0.029 0.0015 [13]
PPP1R3B 8 rs9987289 9220768 A 0.191 (0.005) 20.090 (BETA) 0.022 4.3610
25 [30]
LPL 8 rs10503669 19891970 A 0.059 (0.006) 0.137 (BETA) 0.035 7.2610
25 [13]
rs10096633 (p) 19875201 T 0.430 (0.039) 0.101 (BETA) 0.017 1.5610
29
ABCA1 9 rs3905000 106696891 A 0.161 (0.011) 20.043 (BETA) 0.022 0.054 [31]
rs13284054 (p) 106708894 C 0.850 (0.005) 0.090 (BETA) 0.027 0.0011
FADS1, FADS2,
FADS3
11 rs174547 61327359 C 0.092 (0.009) 20.055 (BETA) 0.030 0.068 [26]
11 rs1535 (p) 61354548 A 0.820 (0.009) 20.102 (BETA) 0.025 6.7610
25
LIPC 15 rs1800588 56510967 T 0.497 (0.017) 0.102 (BETA) 0.018 1.5610
28 [32]
rs8034802 (p) 56512084 A 0.362 (0.010) 0.104 (BETA) 0.017 1.3610
29
CETP 16 rs3764261 55550825 A 0.305 (0.010) 0.203 (BETA) 0.023 8.6610
218 [13]
rs247617 (n) 55548217 A 0.258 (0.006) 0.260 (BETA) 0.019 1.2610
243
LCAT 16 rs255052 66582496 A 0.218 (0.009) 0.132 (BETA) 0.020 6.6610
211 [13]
PLTP 20 rs7679 44009909 T 0.958 (0.005) 0.052 (BETA) 0.041 0.22 [26]
rs6065904 (p) 43968058 A 0.202 (0.010) 20.0904 (BETA) 0.023 7.4610
25
LDL-C DOCK7 1 rs10889353 62890784 A 0.618 (0.012) 0.049 (BETA) 0.017 0.0040 [31]
1 rs10889335 (p) 62732689 A 0.606 (0.018) 0.068 (BETA) 0.018 1.2610
24
CELSR2, PSRC1,
SORT1
1 rs12740374 109619113 T 0.235 (0.003) 20.174 (BETA) 0.021 1.3610
216 [26]
PCSK9 1 rs10493178 (n) 55369655 A 0.878 (0.007) 0.177 (BETA) 0.025 4.7610
212
APOB 2 rs562338 21141826 A 0.598 (0.009) 20.089 (BETA) 0.017 3.1610
27 [32]
rs503662 (p) 21267647 T 0.652 (0.010) 20.110 (BETA) 0.018 2.5610
29
LDLR 19 rs6511720 11063306 T 0.144 (0.002) 20.208 (BETA) 0.038 7.2610
28 [26]
APOE, APOC1,
APOC4, APOC2
19 rs1160985 (n) 50095252 T 0.635 (0.011) 20.166 (BETA) 0.017 7.2610
221
To be included in this table, we require a two-tailed P#0.05 after Bonferroni correction for the number of independent loci reported in the NHGRI database (Table S5).
We report the association results for the published (index) SNP, unless it is not available. In that case, we report results for a proxy SNP (r
2$0.5 with original SNP in
HapMap CEU; see Table S5 for additional details).
aProxy SNPs are marked with (p). SNPs that have a strong association signal but are not in LD with the published SNP are marked with (n) as potentially novel.
bPosition on NCBI build 36.1.
cEffect alleles are given on the forward strand. For proxy SNPs, we phased HapMap CEU genotypes for the index and proxy SNPs to determine haplotypes, to be able to
assess consistency of the direction of effect.
dFor dichotomous phenotypes, we report odds ratio (OR) and 95% confidence interval (CI); for quantitative traits, we report effect size (beta, in standard deviation units)
and standard error (SE).
eP-values are corrected using genomic control.
doi:10.1371/journal.pgen.1001300.t003
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Most large-scale genetic efforts to identify risk factors for CHD have
focused so far on populations of European ancestry. Given the
prevalence of the disease in African Americans, and the development
of better genotyping platforms that more completely survey common
genetic variation in African-derived genomes [16], it is now both
pertinent and timely to investigate the genetics of CHD in populations
of African ancestry. The CARe Project was launched four years ago
with the specific goal to create a resource for association studies of
various heart-, lung-, and blood-related phenotypes across different
ethnic groups [15]. In this article, we present results from the largest
GWAS to date for CHD and its risk factors in African Americans.
Despite being the largest, the size of our GWAS is modest compared
to that of some European-derived consortia. As a consequence, we
had limited discovery power and did not identify novel loci specifically
associated with CHD or its risk factors that reach genome-wide
significance in our African-American dataset.
We also attempted to replicate in the CARe African-American
participants genetic associations to CHD and its risk factors
previously identified in Caucasians. We could replicate 17 of those
associations; for many of them, this was the first replication in a non-
European-derived population (Table 3). For five of these 17
associations, we showed how cross-ethnic comparisons of genetic
association results may help refine genomic intervals carrying causal
alleles(Figure2andFigureS3).Therewere,however,alargenumber
of loci originally found in Caucasians that were not replicated in the
CARe meta-analyses presented in this manuscript (Table S11).
Because our sample size was relatively modest, that we used stringent
statistical thresholds to declare repli c a t i o ni no r d e rt oc o n t r o lo u rf a l s e
positive rate,and that effectsizescould be weaker forgivenlociacross
different ethnic groups, our limited power probably explains why
Figure 2. HDL-C association results in Caucasians (top panel) [26] and in the CARe African Americans (bottom panel) at the FADS
locus. Plots were generated using LocusZoom [33]. Under the top panel, the light blue box corresponds to the chromosomal interval flanked by the
leftmost and rightmost SNPs with a r
2$0.3 with the index SNP rs174547 in HapMap CEU. In the bottom panel, there is no light blue box because the
top CARe SNPs at this locus, rs1535, is not in strong LD with any markers in HapMap YRI.
doi:10.1371/journal.pgen.1001300.g002
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Alternatively, some of these non-replications could be explained by
the absence of variants within these loci associated with these traits in
African Americans. Our data does not allow us to distinguish these
two possibilities, and larger replication studies in African-American
cohorts will be needed to draw informative conclusions.
Taken together, our results suggest that CHD risk in African
Americans is not influenced by loci with major phenotypic effect
on disease risk, but rather by multiple variants of weak effect, as we
have observed for CHD and other traits in Caucasians. Because
opportunities for replication and meta-analysis with other African-
American cohorts are evolving rapidly, the CARe dataset is an
outstanding public resource that provides a strong base for
discovery of genetic contributors to CHD in non-European-
derived populations.
Materials and Methods
Ethics statement
All participants gave informed written consent. The CARe
project is approved by the ethic committees of the participating
studies and of the Massachusetts Institute of Technology.
Studies
African-American participants for the GWAS were drawn from
five population-based studies: Atherosclerosis Risk in Communi-
ties (ARIC; N=3,269), Coronary Artery Risk Development in
young Adults (CARDIA; N=1,209), Cleveland Family Study
(CFS; N=704), Jackson Heart Study (JHS; N=2,200), and Multi-
Ethnic Study of Atherosclerosis (MESA; N=1,737). Although
longitudinal data is available for most participants, only informa-
tion collected at recruitment was considered in this GWAS.
Replication results for top SNP associations were obtained using in
silico or de novo genotyping from four African-American and
African-Caribbean population-based cohorts (Health, Aging,
and Body Composition Study (Health ABC; N=1,119), National
Health and Nutrition Examination Survey III (NHANES III,
N=1,720), Jamaica Spanish Town (SPT, N=1,746) and
Jamaica GXE (N=969), one nested case-control panel from
the population-based Multiethnic Cohort (MEC, N=2,184),
and two case-control panels (Cleveland Clinic, N=620,
and PennCATH, N=491). A detailed description of all cohorts
and phenotype definitions used in this study is provided in Text
S1.
Table 4. Top novel associations (P#1610
26) identified using SNP genotype and estimate of local African versus European
ancestry.
TRAIT SNP
CHR
(POS)1
Reference
allele
Reference allele
frequency SNP-only
SNP+Estimate of
local ancestry
Closest
genes7
CARe
2 CEU YRI Beta (SE)
3 P-value
4 Zgeno
5 Zloc.anc
6 P-value
4
Coronary heart
disease
rs6674681 1 (79493711) T 0.75 0.23 0.88 0.0892
(0.1151)
0.44 3.524 24.14 3.8610
27
rs6753112 2 (231895399) T 0.87 0.31 0.91 20.2459
(0.1357)
0.07 23.977 3.625 5.2610
27 ARMC9
HDL-C rs8078633 17 (559286) C 0.31 1.00 0.18 20.0006
(0.0186)
0.98 23.893 4.723 3.6610
27 APPBP2
Hypertension rs10218356 23 (19168233) A 0.20 0.94 0.04 20.0915
(0.0523)
0.08 24.056 3.891 6.5610
27
LDL-C rs17441606 2 (19431916) A 0.17 0.32 0.11 20.0759
(0.0219)
6.2610
24 24.234 4.021 4.0610
28 OSR1
rs9306885 2 (19852313) T 0.26 0.72 0.16 20.0329
(0.0197)
0.10 24.144 4.321 1.7610
28
rs6728440 2 (19862827) A 0.96 0.87 1.00 0.0978
(0.0446)
0.03 3.527 24.029 5.9610
28 TTC32
rs7560236 2 (22930288) T 0.06 0 0.08 0.1493
(0.0366)
5.5610
25 4.568 3.804 2.1610
28
rs6748157 2 (28586865) A 0.86 0.51 0.98 0.03
(0.0247)
0.23 3.592 24.062 4.1610
28 PLB1
Smoking rs7075036 10 (16904816) T 0.69 0.32 0.80 20.1326
(0.0296)
8.4610
26 25.036 2.054 8.0610
27 RSU1,
CUBN
rs11088655 21 (18128360) T 0.41 0.22 0.52 0.0938
(0.0275)
6.9610
24 4.347 3.637 2.4610
27 C21orf91
rs16982414 21 (28711411) T 0.90 0.99 0.84 20.1646
(0.0432)
1.5610
24 24.375 23.327 6.0610
27
Global ancestry is included in the model for both methods.
1Coordinates are on NCBI build 36.1.
2Average frequency for the reference allele across all available African American CARe samples.
3Direction of the effect given for the reference allele; SE, standard error.
4P-values are scaled using genomic control.
5Z-score for the SNP genotype information. A Z-score .0 means that the trait (or the risk to develop the disease) increases with the number of copies of reference
alleles.
6Z-score for the local ancestry estimate information. A Z-score .0 means that the trait (or the risk to develop the disease) increases with the number of copies of
European chromosomes.
7Genes in a 200 kb window.
doi:10.1371/journal.pgen.1001300.t004
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All discovery samples (GWAS) were genotyped on the Affymetrix
Genome-Wide Human SNP array 6.0 according to the manufacturer’s
protocol. For replication, the MEC samples were genotyped by
Taqman, and the NHANES III, Jamaica SPT, Jamaica GXE,
Cleveland, and UPENN samples were genotyped using Illumina’s
Oligos Pool All (OPA) technology. The Health ABC samples were
genotyped on the Illumina Human1M-Duo BeadChip array as part of
an independent GWAS; SNP results for the replication of the CARe
findings were extracted and analyzed. Several quality control (QC)
filters were applied to the genome-wide genotype data: DNA
concordance checks; sample and SNP genotyping success rate
(.95%, minor allele frequency $1%); sample heterozygosity rate,
identity-by-descent analysis to identify population outliers (Figure S1),
problematic samples, and cryptic relatedness; Mendel errors rate in
CFS and JHS, and SNP association with chemistry plates. For
replication, SNPs and samples with genotyping success rate ,90%
were excluded. Because of the admixed nature of the participants,
SNPs were not removed solely because they departed from Hardy-
Weinberg equilibrium. A detailed description of the quality control
checks applied to the discovery (GWAS) and replication genotyping
data can be found in Text S1.
SNP imputation
To increase coverage and facilitate comparison with other
datasets, we imputed genotype data using MACH v1.0.16 [19].
We built a panel of reference haplotypes using HapMap phase II
CEU and YRI data, and imputed SNP genotypes using all
Affymetrix 6.0 SNPs that passed the QC steps described above.
Using and independent dataset of ,12,000 SNPs genotyped on
the same DNA but with a different platform, we estimated an
allelic concordance rate of 95.6% (Text S1).
Association analyses
SNP-only based genetic association analysis of quantitative (HDL-
C, LDL-C, smoking) and dichotomous (coronary heart disease, type-
2 diabetes, hypertension) traits were carried out using linear and
logistic statistical framework, respectively, in PLINK (unrelated
cohorts: ARIC, CARDIA, JHS, MESA, UPENN, Cleveland, MEC,
NHANES III, and Health ABC) or using R scripts that model family
structure (related cohort: CFS) [28]. For the cohorts with genome-
wide genotyping data available, the first ten principal components
were included in each analysis to account for population stratifica-
tion and admixture. The method to estimate local ancestry was
implemented in ANCESTRYMAP and is described in details in Text
S1. To combine allelic and local ancestry information (Table 4), we
calculated a chi-square statistic with two degrees-of-freedom.
Association results were combined across cohorts using an inverse
variance meta-analysis approach as implemented in metal.
URL
CARe: http://www.broadinstitute.org/gen_analysis/care/index.
php/Main_Page; MACH: http://www.sph.umich.edu/csg/abecasis/
MACH; METAL: http://www.sph.umich.edu/csg/abecasis/Metal/
i n d e x . h t m l ;P L I N K :h t t p : / /pngu.mgh.harvard.edu/,purcell/plink.
Supporting Information
Figure S1 Plots of the two main principal components (PC) in the
CARe African-American samples. European-Americans and Niger-
ians samples are used as reference populations. We note that the first
principal component (PC1) captures European vs. African global
ancestry. For CFS, outliers on PC2 all belong to the same large family.
Found at: doi:10.1371/journal.pgen.1001300.s001 (0.25 MB TIF)
Figure S2 Manhattan plots summarizing the meta-analysis
results for the six phenotypes analyzed after double genomic
control scaling. The dashed line highlights genome-wide signifi-
cance (P-value=5610
28). The genome-wide significant loci
include 8p23 (chr8), LPL (chr8), LIPC (chr15), LCAT (chr16),
and CETP (chr16) for HDL-C, SLC12A9 (chr7) for hypertension,
and PCSK9 (chr1), CELSR2-PSRC1-SORT1 (chr1), and APOE
(chr19) for LDL-C.
Found at: doi:10.1371/journal.pgen.1001300.s002 (1.27 MB TIF)
Figure S3 Graphical representation of the information summarized
in Table S12. Plots were drawn using LocusZoom [26]. CHD
association results in Caucasians are from Kathiresan et al. [27]. HDL-
C association results in Caucasians are from Kath-
iresan et al. [28]. Under each plot, the light blue box corresponds to
the genomic intervals flanked by the leftmost and rightmost SNPs with
and r
2$0.3 with the index SNPs (purple diamond). For the results in
Caucasians, we used LD based on HapMap CEU, and for the results
in African Americans, LD based on HapMap YRI. For the PLTP and
ABCA1 loci, the CARe SNPs (respectively rs6065904 and rs13284054)
define genomic intervals of 0.2 kb using the r
2$0.3 threshold, which
appear as light blue lines on the plots.
Found at: doi:10.1371/journal.pgen.1001300.s003 (1.59 MB TIF)
Figure S4 Quantile-quantile (QQ) plots of the meta-analyses
results that take into account local ancestry estimates and SNP
genotypes (Chi-square with two degrees-of-freedom (N=8,090).
Each black circle represents an observed statistic for genotyped
SNPs only (defined as the 2log10(P-value)) against the corre-
sponding expected statistic. The grey area corresponds to the 90%
confidence intervals calculated empirically using permutations.
The meta-analysis inflation factors are: coronary heart disease
(ls=0.923), HDL-C (ls=1.030), hypertension (ls=1.121), LDL-
C( ls=1.290), smoking (ls=1.060), and type-2 diabetes
(ls=1.109). Data shown is genomic controlled before (for each
study) and after the meta-analysis.
Found at: doi:10.1371/journal.pgen.1001300.s004 (0.26 MB TIF)
Figure S5 Manhattan plots summarizing the meta-analysis
results that take into account local ancestry estimates and SNP
genotypes (two degrees-of-freedom). Results are shown for the six
phenotypes analyzed after double genomic control scaling. The
dashed line highlights genome-wide significance (P-val-
ue=5610
28). The genome-wide significant loci include LCAT
(chr16) and CETP (chr16) for HDL-C and PCSK9 (chr1), CELSR2-
PSRC1-SORT1 (chr1), 2p24 (chr2), and APOE (chr19) for LDL-C.
Found at: doi:10.1371/journal.pgen.1001300.s005 (1.23 MB TIF)
Figure S6 Comparison of P-values (-log10 scale) for the meta-
analysis results obtained using SNP genotype-only (x-axis) or SNP
genotype+estimate of local ancestry (y-axis) to compute the test
statistics. Each black circle corresponds to a SNP. In total, results
from ,885,000 genotyped SNPs were available for each method.
The gray line represents perfect correlation (x=y). The horizontal
and vertical dashed lines represent the pre-defined threshold for
genome-wide significance (P-value=5610
28).
Found at: doi:10.1371/journal.pgen.1001300.s006 (0.45 MB TIF)
Table S1 Sample exclusion for the CARe Affy6.0 datasets.
Found at: doi:10.1371/journal.pgen.1001300.s007 (0.05 MB
DOC)
Table S2 SNP exclusion for the CARe Affy6.0 datasets.
Found at: doi:10.1371/journal.pgen.1001300.s008 (0.04 MB
DOC)
Table S3 Power calculations for the different phenotypes
analyzed by the CARe Project in this study. The assumptions
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10%, and an alpha threshold of 1610
26 (which was arbitrary
selected to promote SNPs for replication). We also assume that all
samples belong to a single study; in practice, there is a small loss of
power because of the meta-analysis. For case-control, power
calculations were done using the Genetic Power Calculator
(http://pngu.mgh.harvard.edu/,purcell/gpc/). For quantitative
traits, power calculations were done using Quanto (http://hydra.
usc.edu/gxe/).
Found at: doi:10.1371/journal.pgen.1001300.s009 (0.04 MB
DOC)
Table S4 Inflation factors (ls) for the different phenotypes
analyzed, by cohort and for the corresponding meta-analyses.
Found at: doi:10.1371/journal.pgen.1001300.s010 (0.04 MB
DOC)
Table S5 Coronary heart disease replication results for SNPs
from the CARe meta-analysis.
Found at: doi:10.1371/journal.pgen.1001300.s011 (0.25 MB
DOC)
Table S6 HDL-C replication results for SNPs from the CARe
meta-analysis.
Found at: doi:10.1371/journal.pgen.1001300.s012 (0.21 MB
DOC)
Table S7 Hypertension replication results for SNPs from the
CARe meta-analysis.
Found at: doi:10.1371/journal.pgen.1001300.s013 (0.21 MB
DOC)
Table S8 LDL-C replication results for SNPs from the CARe
meta-analysis.
Found at: doi:10.1371/journal.pgen.1001300.s014 (0.22 MB
DOC)
Table S9 Type-2 diabetes replication results for SNPs from the
CARe meta-analysis.
Found at: doi:10.1371/journal.pgen.1001300.s015 (0.10 MB
DOC)
Table S10 Loci associated at genome-wide significance level
with CHD or its risk factors in Caucasians (data retrieved from the
NHGRI database; http://www.genome.gov/26525384).
Found at: doi:10.1371/journal.pgen.1001300.s016 (0.30 MB
DOC)
Table S11 CARe meta-analysis association results (including
data from ARIC, CARDIA, CFS, JHS, and MESA) for the SNPs
associated with coronary heart disease and its risk factors in
Caucasians. In yellow, we highlight the five loci where association
signals in African Americans define smaller genomic intervals to
search for causal allele(s).
Found at: doi:10.1371/journal.pgen.1001300.s017 (0.32 MB
DOC)
Table S12 Linkage disequilibrium-based genomic intervals of
loci previously associated with coronary heart disease and HDL-C
in Caucasians using the CARe datasets.
Found at: doi:10.1371/journal.pgen.1001300.s018 (0.05 MB
DOC)
Text S1 Supporting information.
Found at: doi:10.1371/journal.pgen.1001300.s019 (0.27 MB
DOC)
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